Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06367673
Status:
RECRUITING
Last Update Posted:
2024-04-18
First Post:
2024-04-11
Brief Title:
Natural KillerNK Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia
Sponsor:
Zhejiang University
Organization:
Zhejiang University
Study Overview
Official Title:
Clinical Study to Evaluate the Safety and Efficacy of iPSC -NK Cells Targeting CLL1 or CD33 in Patients With RelapsedRefractory AML
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 1 first-in-human FIH open-label multicohort study to evaluate the safety tolerability and preliminary efficacy of CLL1 or CD33 target Chimeric antigen receptor CAR -induced pluripotent stem cells derived NK cells in patients with relapsedrefractory AML
Detailed Description:
Acute myelogenous leukemia AML is a potentially cur-able disease 70 of newly diagnosed patients achievecomplete remission with first-line therapy but prognosisworsens for relapsed disease in both pediatric and adultpatientsC-type lectin-like molecule-1 and cluster of differentiation antigen 33 has attracted the researchers attention due to its high expression in AML while being absent in normal hematopoietic stem cell Accumulating evidence have demonstrated CLL-1 or CD33 is an ideal target for AML
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None